Clinical evaluation of indoramin, a new antihypertensive agent.
D000804:Angiotensin II / Q000494:pharmacology; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001549:Benzamides / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004361:Drug Tolerance; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use*; D007545:Isoproterenol / Q000494:pharmacology; D008297:Male; D009638:Norepinephrine / Q000494:pharmacology; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use*; D010919:Placebos; D012044:Regression Analysis; D013997:Time Factors
D000959:Antihypertensive Agents; D001549:Benzamides; D007211:Indoles; D010880:Piperidines; D010919:Placebos; D000804:Angiotensin II; D007545:Isoproterenol; D009638:Norepinephrine